Related Experiment Video
Updated: Nov 19, 2025
07:08
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
1.1K
[Correlations between pancreatic carcinoma and previous neoplasms.]
Francesca Gavazzi1, Laura Giordano2, Martina Nebbia3
1UO Chirurgia Pancreatica, Humanitas Clinical and Research Center - IRCCS, Rozzano (Milano).
Recenti Progressi in Medicina
|January 29, 2021
Summary
Pancreatic cancer (PDAC) patients often have family members with breast or prostate cancer. However, a history of these cancers in relatives or the patient did not significantly impact PDAC survival outcomes.
Area of Science:
- Oncology
- Genetics
- Epidemiology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) prevalence may be elevated in relatives of breast cancer patients.
- BRCA1/2 mutations and variants of uncertain significance (VUS) are potential contributing factors.
Purpose of the Study:
- To investigate the prevalence of neoplastic family history and prior malignancies in patients with PDAC.
- To evaluate the impact of family history and personal pathological history on overall survival (OS) and progression-free survival (PFS) in PDAC patients.
Main Methods:
- Retrospective analysis of 483 PDAC patients who underwent resection between 2010 and 2018.
- Evaluation of family history of cancer and personal history of breast and prostate tumors.
- Calculation of OS and PFS for different patient subgroups.
Main Results:
- 57% of PDAC patients had a positive family history of cancer; 25% had a relative with PDAC, breast, or prostate cancer (88% first-degree relatives).
- 22% of patients had a prior neoplasia (8% breast cancer, 4% prostate cancer).
- Neither family history nor personal pathological history showed a statistically significant impact on OS or PFS.
Conclusions:
- A high prevalence of breast and prostate cancer exists in the families of PDAC patients.
- Prior treated malignancies in PDAC patients do not appear to influence their prognosis.
